RNA epigenetic cancer company Accent adds $63M in series B round

Accent has raised $63 million in a series B financing to progress at least one RNA modification program for cancer into the clinic.

Existing investor EcoR1 Capital led the round. New investors GV, AbbVie Ventures, The Mark Foundation for Cancer Research, NS Investment and Droia Ventures also participated, as did existing investors Atlas Venture and The Column Group...